Carboplatin News and Research

RSS
Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers).
Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Pathologic complete response after presurgery chemotherapy increases overall survival for TNBC patients

Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Chemotherapy treatment can contribute to long-term neurocognitive deficits in pediatric brain tumor survivors

Chemotherapy treatment can contribute to long-term neurocognitive deficits in pediatric brain tumor survivors

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

Combining chemotherapy and birinapant effective against high-grade serous ovarian cancer

UofL conducts Phase I research study for children with relapsed tumors

UofL conducts Phase I research study for children with relapsed tumors

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

Paclitaxel-fostamatinib combination therapy may reduce size of ovarian cancer cells

No overall survival benefit for bevacizumab in ovarian cancer

No overall survival benefit for bevacizumab in ovarian cancer

Study: Intravenous nutrition source may significantly reduce toxicity of platinum-based cancer drugs

Study: Intravenous nutrition source may significantly reduce toxicity of platinum-based cancer drugs

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

New clinical studies on Myriad Genetics myChoice HRD companion diagnostic test presented at ASCO 2015

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Myriad Genetics announces new clinical studies on myChoice HRD companion diagnostic test at ASCO 2015

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer

Cantrixil drug granted FDA Orphan Drug Designation for treatment of ovarian cancer